Reduce cognitive decline through exercise
- Trial ID
- NCT07324330
- Official Title
- Slowing Cognitive Decline in Alpha-synucleinopathies by Enhancing Physical Activity
- Goal
- Reduce cognitive decline through exercise
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- University Hospital, Bonn
- Study Type
- INTERVENTIONAL
- Enrollment
- 130 participants
- Conditions
- Parkinson Disease, Prodromal Stage, Neurodegenerative Diseases, Basal Ganglia Diseases, Central Nervous System Diseases, Synucleinopathies, Nervous System Diseases, Cerebral Disorder, Brain Diseases, Parkinsonian Disorders
- Interventions
- Increase of physical activity volume and intensity with the use of a motivational smartphone application
Plain-Language Summary
The goal is to slow early cognitive decline linked to alpha-synuclein disorders by boosting physical activity in people at high risk of Parkinson's, especially those with polysomnography-confirmed idiopathic REM sleep behavior disorder. The approach uses a motivational smartphone app that tracks steps and activity and gives tailored prompts to raise daily volume and intensity of exercise, because more regular, higher-intensity movement can improve brain blood flow and neuroplasticity and may help slow cognitive changes. It is a non-drug, lifestyle intervention, so it does not interact with medications like levodopa. The trial is looking for adults 50 to 80 years old, both iRBD patients and healthy controls, who average under 10,000 steps per day, have basic smartphone skills and German fluency, own a compatible phone, and do not have major cardiovascular disease or significant cognitive or dexterity problems.
Locations
- University Hospital of Bonn, Bonn, North Rhine West-Falia, Germany
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Increase of physical activity volume and intensity with the use of a motivational smartphone application. The goal is to slow early cognitive decline linked to alpha-synuclein disorders by boosting physical activity in people at high risk of Parkinson's, especially those with polysomnography-confirmed idiopathic REM sleep behavior disorder. The approach uses a motivational smartphone app that tracks steps and activity and gives tailored prompts to raise daily volume and intensity of exercise, because more regular, higher-intensity movement can improve brain blood flow and neuroplasticity and may help slow cognitive changes. It is a non-drug, lifestyle intervention, so it does not interact with medications like levodopa. The trial is looking for adults 50 to 80 years old, both iRBD patients and healthy controls, who average under 10,000 steps per day, have basic smartphone skills and German fluency, own a compatible phone, and do not have major cardiovascular disease or significant cognitive or dexterity problems.
- Who can participate?
- Participants must be between 50 Years and 80 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 3 years.